RARE
Ultragenyx Pharmaceutical Inc.Company with tickers: RARE
CIK
1515673
CUSIP
90400D108
Shares Outstanding
98,489,224
Website
https://www.ultragenyx.com
13F Activity (30d)
13 filings
2 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Daniel G. Welch | Class I Director | Appointed | 2026-05-18 |
| Shehnaaz Suliman | Class I Director | Appointed | 2026-05-18 |
| Emil D. Kakkis | Class I Director | Appointed | 2026-05-18 |